Houston (AP) The 2012 Susan G. Komen Race for the Cure® In Houston Was The Best In The History Of The Race. An Un-offical counts was over one hundred thousand.
With so many people participating in this years Susan G. Komen Race for the Cure® event Barron's Medical Journal Robert Reports GenNXeix Biotech CEO says that genomics and genes is what next for a breast cancer cure. The latest finding is although still in the early stages of research, molecular breast cancer subtypes may become useful in planning treatment and developing new therapies. Most studies divide breast cancer into four major molecular subtypes: Luminal A, Luminal B, Triple negative/basal-like,and HER2 type
What the fust is all about is scientist recognized something call Luminal subtypes. Luminal subtypes had the lowest overall mutation rate, but by contrast, had the largest number of genes observed to be significantly mutated. This suggests that each of the genes identified as significantly mutated in the Luminal subtypes is more likely to be important in fueling cancer progression. The Luminal subtypes are characterized by the specific expression signature of multiple so-called transcription-factor genes, including ESR1, GATA3, FOXA1, XBP1 and cMYB.
Everyone had a great time, this years event was well represented by The Houston Business Community.
Click to See Saving From Robert Graham Houston Galleria Store
No comments:
Post a Comment